Regenity Biosciences Completes 1st Surgery with RejuvaKnee

Regenity Biosciences announced the successful completion of the first surgery using RejuvaKnee, its collagen-based meniscal implant designed to be implanted arthroscopically to reinforce and repair soft tissue injuries of the meniscus.

Paul Fleissner, MD, an orthopedic surgeon at the Crystal Clinic in Akron, OH, performed the surgery utilizing the RejuvaKnee implant to treat a college-aged athlete suffering from chronic pain following a prior meniscectomy.

The RejuvaKnee implant is FDA-cleared as a regenerative implant device for meniscal repair. It is designed to facilitate the regeneration of native meniscal tissue, enabling a more complete recovery as compared to removing or replacing the meniscus. 

“I believe the RejuvaKnee implant has the potential to be a game-changer for meniscal restoration, especially for younger patients under forty seeking the most durable procedure,” said Dr. Fleissner. “The device offers excellent handling properties, is user-friendly for surgeons, and serves as a convenient ‘off-the-shelf’ solution for those who have irreparable tears or have previously lost meniscal tissue.”

In a 12-month animal study, the implant demonstrated the ability to regenerate meniscal tissue that withstands full weight-bearing within three months, restoring the knee’s normal range of motion.¹

“The first surgery using RejuvaKnee is another meaningful milestone for Regenity, highlighting our mission to improve patient outcomes through regenerative medicine,” said Shawn McCarthy, CEO of Regenity Biosciences. “With RejuvaKnee, we’re helping patients restore quality of life through tissue regeneration. This innovation underscores our leadership commitment to advancing next-generation solutions in Sports Medicine and making what should be a patient’s first surgery last.”

References:

¹ Regenity Data on File, 2024